Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.
Click here for original story, Preliminary results of two large immune therapy studies show promise in advanced cervical cancer
Source: ScienceDaily